Company profile
LEONABIO, INC.
NASDAQ:LONABiotechnology: Biological Products (No Diagnostic Substances)
Drug pipeline (1)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| FOSGONIMETON SODIUM | phase2_3 | — | 5 | completed, terminated |
Revenue is the latest quarter the company reported for that product, from SEC filings; a fourth quarter is the year less nine months when no filing states one. Trial counts are of the product's ingredients, deduplicated by trial, so products sharing an ingredient share trials.
Clinical trials (9)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT06432647 | phase1 | completed | 2024-04-24 | 2024-11-25 | LeonaBio | A SAD and MAD Study of the Safety, Tolerability, and Pharmacokinetics of ATH-1105 |
| NCT04491006 | phase2 | completed | 2020-11-23 | 2022-05-20 | LeonaBio | A Study of ATH-1017 in Mild to Moderate Alzheimer's Disease |
| NCT05511558 | phase1 | completed | 2022-07-13 | 2022-10-18 | LeonaBio | A Study of the Absorption, Metabolism, and Excretion of [14C]-Fosgonimeton (ATH-1017) |
| NCT04831281 | phase2 | terminated | 2022-01-20 | 2023-04-19 | LeonaBio | ATH-1017 Treatment in Subjects With Parkinson's Disease Dementia or Dementia With Lewy Bodies (SHAPE Trial) |
| NCT04488419 | phase2_3 | completed | 2020-09-28 | 2024-07-15 | LeonaBio | ATH-1017 for Treatment of Mild to Moderate Alzheimer's Disease |
FDA applications (0)
No records yet.